The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...
Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A ExpertiseNORFOLK, Va.--(BUSINESS WIRE)--ReAlta ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
In the sophisticated world of endocrinology and molecular biology, few compounds have sparked as much curiosity as CJC-1295 DAC. As a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback